Ocular Therapeutix Inc
$ 8.51
-1.33%
24 Jul - close price
- Market Cap 1,862,258,000 USD
- Current Price $ 8.51
- High / Low $ 8.70 / 8.43
- Stock P/E N/A
- Book Value 2.66
- EPS -1.42
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.69 %
- 52 Week High 16.44
- 52 Week Low 6.23
About
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.
Analyst Target Price
$27.09
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-05 | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-03-03 | 2024-11-14 | 2024-08-07 | 2024-05-07 | 2024-03-11 | 2023-11-07 | 2023-08-07 |
| Reported EPS | -0.4 | -0.29 | -0.38 | -0.39 | -0.37 | -0.29 | -0.22 | -0.26 | -0.24 | -0.35 | -0.19 | -0.26 |
| Estimated EPS | -0.31 | -0.34 | -0.35 | -0.35 | -0.28 | -0.22 | -0.21 | -0.21 | -0.18 | -0.3 | -0.25 | -0.29 |
| Surprise | -0.09 | 0.05 | -0.03 | -0.04 | -0.09 | -0.07 | -0.01 | -0.05 | -0.06 | -0.05 | 0.06 | 0.03 |
| Surprise Percentage | -29.0323% | 14.7059% | -8.5714% | -11.4286% | -32.1429% | -31.8182% | -4.7619% | -23.8095% | -33.3333% | -16.6667% | 24% | 10.3448% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.4 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCUL
2026-07-23 13:06:00
This article analyzes Ocular Therapeutix Inc. (NASDAQ: OCUL) using AI models, indicating weak sentiment across all time horizons and suggesting a short bias. It details three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights an exceptional risk-reward setup targeting a 21.9% gain versus 0.2% risk and provides multi-timeframe signal analysis for support and resistance levels.
2026-07-12 01:41:34
This article from Stock Traders Daily provides a detailed AI-driven analysis of Ocular Therapeutix Inc. (NASDAQ: OCUL), highlighting strong near and mid-term sentiment potentially shifting to a weak long-term outlook. It outlines specific institutional trading strategies, including long, breakout, and short positions, complete with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
2026-07-10 07:11:15
Ocular Therapeutix, Inc. announced inducement grants to eleven new non-executive employees, consisting of stock options and restricted stock units. These awards, totaling 34,700 shares for options and 11,375 for RSUs, were made under Ocular’s 2019 Inducement Stock Incentive Plan as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants vest over several years, subject to continued service.
2026-07-10 05:09:42
Ocular Therapeutix (OCUL) was recently added to several Russell Value indexes, which could increase its visibility to institutional investors and improve trading volumes. While this inclusion may boost short-term liquidity, the company's long-term investment narrative remains dependent on the success of its AXPAXLI clinical trials and regulatory approvals for wet AMD therapy. Investors should be aware of key risks such as AXPAXLI dependence, cash burn, and potential shareholder dilution, despite optimistic revenue forecasts and a projected fair value of $26.00 by 2029.
2026-07-09 20:43:55
Ocular Therapeutix, Inc. announced inducement awards granted to eleven new non-executive employees under its 2019 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards, effective July 6, 2026, include non-statutory stock options for 34,700 shares and restricted stock units for 11,375 shares, designed to incentivize new hires. The awards vest over several years, contingent on continued employment.
2026-07-09 20:05:00
Ocular Therapeutix, Inc. announced inducement grants to eleven new non-executive employees under Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment. These awards, effective July 6, 2026, include stock options for 34,700 shares and restricted stock units for 11,375 shares, vesting over three to four years. The grants are part of the company's 2019 Inducement Stock Incentive Plan.
